Hybio Pharmaceutical Co., Ltd.

300199

CNE1000011T7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 14/06/2024 am IST			5-day change	1st Jan Change
10.81 ^CNY	+0.75%		+1.98%	-20.40%

29/05	3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection	MT
29/05	Hybio Pharmaceutical Grants Commercial Rights of Weight Loss Drug to Sansheng Mandi Pharmaceutical	MT

Shaogui Zeng Submits a Proposal to Hybio Pharmaceutical to Nominate a Supervisor Candidate

March 12, 2020 at 09:30 am IST

On March 12, 2020, Zeng Shaogui submitted a proposal to Hybio Pharmaceutical Co., Ltd. to nominate Zhenqiong Huang as a Supervisor candidate for the Board of Supervisors of the company due to a low number of current members of the board.

Latest news about Hybio Pharmaceutical Co., Ltd.

3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection	29/05	MT
Hybio Pharmaceutical Grants Commercial Rights of Weight Loss Drug to Sansheng Mandi Pharmaceutical	29/05	MT
Hybio Pharmaceutical Gets Nod to Market Ganirelix Acetate Injection	28/05	MT
Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee	21/05	MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/04	CI
Production Line of Hybio Pharma's Unit Passes Australian Regulator's Inspection	25/04	MT
Hybio Pharmaceutical Gets Regulatory Nod to Test Weight Management Injection; Shares Up 5%	18/04	MT
Hybio Pharmaceutical Gets Nod to Trial Semaglutide Injection; Shares Down 4%	06/12	MT
Hybio Pharmaceutical Receives $14.1 Million Worth of Orders from US Company; Shares Up 6%	06/11	MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Hybio Pharmaceutical Gets Nod to Trial COVID-19 Nasal Spray	21/23/21	MT
Hybio Lands $30 Million Bulk Pharma Chemical Supply Deal With Overseas Client	21/23/21	MT
Hybio Pharmaceutical Co., Ltd.(XSEC:300199) added to S&P Global BMI Index	18/23/18	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	14/23/14	CI
Hybio Pharmaceutical Co., Ltd. announced that it expects to receive CNY 254.12 million in funding	11/23/11	CI
Hybio Pharmaceutical Registers Acetic Acid Pharmaceutical Ingredient	12/23/12	MT
Hybio Pharma’s Carboprost Injection Granted New Indication for Vaginal Delivery	11/23/11	MT
Hybio Pharmaceutical Gets Nod to Trial Linaclotide Capsules	17/23/17	MT
Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology Co., Ltd. from Zhou Zhenke for CNY 0.15 million.	27/23/27	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	26/23/26	CI
Li Xiulan completed the acquisition of 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin.	28/23/28	CI
Hybio Pharma’s COVID-19 Nasal Spray Wins FDA Nod For Clinical Trial	28/23/28	MT
Li Xiulan agreed to acquire a 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin for approximately CNY 450 million.	14/23/14	CI

Chart Hybio Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Hybio Pharmaceutical Co., Ltd. is a China-based company principally involved in the development, manufacture and distribution of chemical synthetic polypeptide pharmaceuticals. The Companyâs products include polypeptide preparations, polypeptide active pharmaceutical ingredients (APIs) and customer polypeptide, among which the preparation products include thymopentin for injection, somatostatin for injection, desmopressin for injection and terlipressin for injection, among others. Through its subsidiaries, the Company's newly added products are pharmaceutical packaging products, medical devices and solid products. The Company is also engaged in provision of related technological services.

Sector

Pharmaceuticals

Calendar

15/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HYBIO PHARMACEUTICAL CO., LTD.	-20.40%	1.32B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.37%	43.54B
OTSUKA HOLDINGS CO., LTD.	+19.44%	21.78B
SANDOZ GROUP AG	+17.85%	15.38B
CIPLA LIMITED	+25.55%	15.12B
ZYDUS LIFESCIENCES LIMITED	+60.99%	13.36B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-15.02%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.17%	5.32B